Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice-Reference-Cited by-同舟云学术

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice

Published:2019-06-10 Issue:6 Volume:1 Page:268-275
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Kataoka Masaharu¹,Satoh Toru²,Matsubara Hiromi³,Yamamoto Koji⁴,Inada Tsukasa⁵,Umezawa Kazunari⁶,Takahashi Tomohiko⁶,Nakano Atsushi⁶,Fukuda Keiichi¹

Affiliation:

1. Department of Cardiology, Keio University School of Medicine

2. Department of Cardiology, Kyorin University School of Medicine

3. Department of Cardiology, National Hospital Organization Okayama Medical Center

4. Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences

5. Department of Cardiology, Cardiovascular Center, Osaka Red Cross Hospital

6. Medical Affairs, GlaxoSmithKline K.K.

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/1/6/1_CR-19-0029/_pdf

Reference15 articles.

1. 1. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.

2. 2. Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014; 118: 414–419.

3. 3. Ogawa A, Satoh T, Tamura Y, Fukuda K, Matsubara H. Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am J Cardiol 2017; 119: 1479–1484.

4. 4. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844.

5. 5. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study;Pulmonary Therapy;2023-11-22

2. Compression Stockings Improve Lower Legs Symptom in Patients with Pulmonary Artery Hypertension Treated by Pulmonary Vasodilators—A Pilot Study;Journal of Clinical Medicine;2023-03-24